Berlin Cures Holding AG emerged as a new firm established in September 2014 with the objective of commercializing a successful research endeavor. A team of researchers from the Max Delbrück Center (MDC), the Charité Berlin and the German Heart Institute Berlin has dedicated over a decade to investigating the role of autoantibodies in heart disease and other autoimmune conditions. Gerd Wallukat, affiliated with MDC, first identified these autoantibodies and provided the initial description in 1987. These autoantibodies exhibit a unique ability to activate cells through a highly specific signaling pathway known as G-protein-coupled receptors.